Skip to content
Evigrade
MajorClass III antiarrhythmic, selective IKr blocker×Macrolide antibiotic

Updated · Methodology

Mechanism

Dofetilide is a class III antiarrhythmic. It blocks the rapid component of the delayed rectifier potassium current (IKr), and QT prolongation depends directly on its plasma concentration (dofetilide label, US Food and Drug Administration, FDA). Erythromycin itself prolongs the QT interval and can cause torsade de pointes (erythromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; erythromycin FDA label), so the effects of the two drugs on QT may add up. Erythromycin is a moderate inhibitor of the CYP3A4 enzyme and of the transporter P-glycoprotein (P-gp) (AEMPS). CYP3A4 metabolises a small part of dofetilide, and the US dofetilide label lists macrolides among the CYP3A4 inhibitors that can increase dofetilide levels (dofetilide FDA label). The kidneys are the main route of dofetilide elimination: about 80% of a dose leaves the body in the urine, mostly unchanged. The documents do not state how much erythromycin changes dofetilide levels (dofetilide FDA label).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The Medication Guide of the US dofetilide label lists the warning signs of a dangerous arrhythmia: feeling faint, dizziness and a fast heartbeat. It warns that torsade de pointes can lead to death (dofetilide label, US Food and Drug Administration, FDA). In people with supraventricular arrhythmias who took dofetilide, torsade de pointes occurred in 0.8%, mostly within the first three days of treatment. Low potassium or magnesium increases the risk (FDA). Erythromycin has been associated with QT prolongation and infrequent cases of arrhythmia. Torsade de pointes and deaths have been reported (erythromycin FDA label; erythromycin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Management

Avoid the combination. The US erythromycin label says to avoid erythromycin in patients receiving class IA or class III antiarrhythmics and names dofetilide among them (erythromycin label, US Food and Drug Administration, FDA). The US dofetilide label does not recommend dofetilide with other drugs that prolong the QT interval and names certain oral macrolides among them. It advises caution when combining dofetilide with CYP3A4 inhibitors, including macrolides (dofetilide FDA label). The Spanish summaries of product characteristics (SmPCs) of originator erythromycin, for infusion and for oral use, advise caution with QT-prolonging drugs. They name class IA and class III antiarrhythmics among these drugs (erythromycin SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Only the SmPC of one generic erythromycin infusion contraindicates use with class IA and class III antiarrhythmics. The SmPC of the originator infusion has no such statement (AEMPS). Dofetilide is not in the Spanish medicines register CIMA. If dofetilide is stopped so that a potentially interacting drug can be given, wait at least two days before starting that drug. When restarting dofetilide, keep the patient for at least three days in a facility that can calculate creatinine clearance, provide continuous electrocardiogram (ECG) monitoring and perform cardiac resuscitation (FDA). Dofetilide is contraindicated if the QT or heart-rate-corrected QT interval (QTc) is above 440 ms (500 ms with ventricular conduction abnormalities). Stop dofetilide if the QTc exceeds 500 ms (550 ms with such abnormalities). Keep potassium in the normal range before and during treatment (FDA). Do not give erythromycin to people with a history of QT prolongation or ventricular arrhythmia, or with low potassium or magnesium (AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dofetilide

Other interactions with Erythromycin